Medpace (MEDP) Competitors

Medpace (NASDAQ:MEDP) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Which has more volatility and risk, MEDP or EXEL?

Medpace has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Do institutionals and insiders believe in MEDP or EXEL?

78.0% of Medpace shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 20.3% of Medpace shares are held by company insiders. Comparatively, 2.9% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is MEDP or EXEL more profitable?

Exelixis has a net margin of 22.43% compared to Medpace's net margin of 17.66%. Medpace's return on equity of 50.87% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.66%	50.87%	19.61%
Exelixis	22.43%	20.99%	16.07%

Does the MarketBeat Community prefer MEDP or EXEL?

Exelixis received 247 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 68.54% of users gave Exelixis an outperform vote while only 63.77% of users gave Medpace an outperform vote.

Company	Underperform	Outperform
Medpace	Outperform Votes 352 63.77%	Underperform Votes 200 36.23%
Exelixis	Outperform Votes 599 68.54%	Underperform Votes 275 31.46%

Do analysts prefer MEDP or EXEL?

Medpace presently has a consensus price target of $380.00, indicating a potential upside of 16.53%. Exelixis has a consensus price target of $31.44, indicating a potential downside of 9.25%. Given Medpace's higher probable upside, equities research analysts clearly believe Medpace is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.45
Exelixis	1 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.65

Which has higher valuation and earnings, MEDP or EXEL?

Medpace has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$1.89B	5.37	$282.81M	$11.42	28.55
Exelixis	$1.83B	5.41	$207.76M	$1.56	22.21

Does the media refer more to MEDP or EXEL?

In the previous week, Exelixis had 2 more articles in the media than Medpace. MarketBeat recorded 11 mentions for Exelixis and 9 mentions for Medpace. Exelixis' average media sentiment score of 0.91 beat Medpace's score of 0.44 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exelixis	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Medpace and Exelixis tied by winning 9 of the 18 factors compared between the two stocks.